Vectibix
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Clinical data | |
| Trade names | Vectibix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607066 |
| Routes of administration |
intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | ∼9.4 days (range: 4-11 days) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C6398H9878N1694O2016S48 |
| Molar mass | 144,324.12 g·mol−1 |
  (what is this?)
|
|
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc.
In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.
It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment. Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008 for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".
Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
Panitumumab was initially approved on September 27, 2006 for EGFR-expressing, metastatic CRC with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens, based on the results of a study which showed clinical benefit in metastatic colorectal cancer patients. In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations.
It is also approved as a first-line agent in combination with FOLFOX.
...
Wikipedia